Once-daily oral icotrokinra outperforms placebo in ulcerative colitis

by Elana Gotkine

edited by Lisa Lock, reviewed by Andrew Zinin

Lisa Lock

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

reputable news agency

proofread

The GIST Add to Preferred Sources

For patients with moderately to severely active ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a clinical response at week 12 significantly more often than placebo, according to a study published in the Oct. 15 issue of the New England Journal of Medicine.

Maria T. Abreu, M.D., from Cedars Sinai in Los Angeles, and colleagues conducted a phase 2, double-blind, randomized trial of oral icotrokinra in adults with moderately to severely active ulcerative colitis. Participants were randomly assigned to receive icotrokinra at a once-daily dose of 400 mg, 200 mg, or 100 mg or placebo (63, 62, 64, and 63 individuals, respectively).

The researchers found that with respect to a clinical response at week 12, all icotrokinra doses were superior to placebo (63%, 58%, and 55% versus 27% in the 400-, 200-, and 100-mg groups versus placebo, respectively). Compared with the placebo group, the 400-mg group had significantly higher percentages of participants with clinical remission at week 12 (30% versus 11%), participants with symptomatic remission (46% versus 19%), and participants with endoscopic improvement (37% versus 14%).

The percentage of participants with adverse events was 60%, 66%, 66%, and 62% in the 400-, 200-, and 100-mg groups and the placebo group, respectively, through week 28; the corresponding percentages of serious adverse events were 2%, 5%, 0%, and 10%.

"Icotrokinra was effective even in hard-to-treat patients who had failed previous drug regimens," Abreu said in a statement. "The fact that the medicine can be taken orally will help us improve the range of options we have for treating patients."

Publication details

Maria T. Abreu et al., Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis, New England Journal of Medicine (2026). DOI: 10.1056/nejmoa2604435

Journal information: New England Journal of Medicine

Clinical categories

GastroenterologyClinical pharmacology Who's behind this story?

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

© 2026 HealthDay. All rights reserved.

Citation: Once-daily oral icotrokinra outperforms placebo in ulcerative colitis (2026, October 23) retrieved 23 October 2026 from https://medicalxpress.com/news/2026-10-daily-oral-icotrokinra-outperforms-placebo.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.